Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 587.25M P/E - EPS this Y 13.60% Ern Qtrly Grth -
Income -44.05M Forward P/E -4.76 EPS next Y -41.20% 50D Avg Chg 1.00%
Sales 15.13M PEG -0.28 EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.72 EPS next 5Y 145.30% 52W High Chg -46.00%
Recommedations 1.60 Quick Ratio 57.03 Shares Outstanding 52.16M 52W Low Chg 28.00%
Insider Own 9.27% ROA -7.98% Shares Float 32.13M Beta 3.57
Inst Own 98.39% ROE -9.20% Shares Shorted/Prior 3.31M/3.25M Price 12.77
Gross Margin -251.04% Profit Margin -291.17% Avg. Volume 152,358 Target Price 67.50
Oper. Margin -155.36% Earnings Date Aug 7 Volume 62,386 Change -3.55%
About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc. News
12/06/24 Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
12/04/24 Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
12/04/24 Why Janux Therapeutics Crushed the Market Today
12/04/24 JANX Stock Hits Record High on Prostate Cancer Study Data
12/03/24 Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
12/03/24 Janux Therapeutics Announces Proposed Public Offering
12/03/24 Sector Update: Health Care Stocks Mixed Late Afternoon
12/03/24 Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz
12/03/24 Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results
12/03/24 Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year
12/03/24 Janux impresses Wall Street with new prostate cancer drug results
12/02/24 Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
11/25/24 Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
11/23/24 Janux Therapeutics initiated with an Outperform at Leerink
11/15/24 Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
11/08/24 Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations
11/06/24 Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
11/01/24 Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors
10/16/24 Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
10/07/24 Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Reardon Tighe Acting Chief Financi.. Acting Chief Financial Officer Nov 13 Buy 5.87 849,854 4,988,643 849,854 11/15/23
Lichter Jay Director Director Nov 13 Buy 5.87 849,854 4,988,643 849,854 11/15/23
Avalon Ventures XI, L.P. 10% Owner 10% Owner Nov 13 Buy 5.87 849,854 4,988,643 849,854 11/13/23
ORBIMED ADVISORS LLC Director Director Dec 29 Sell 20.3 40,400 820,120 231,098 12/30/21
Thompson Peter A. Director Director Dec 29 Sell 20.3 40,400 820,120 231,098 12/30/21